Key result
Low molecular weight heparin is the preferred safe treatment and prophylactic agent for pregnant women with acute venous thromboembolism or high-risk thrombophilia.
Why the study?
What are the risk factors, diagnosis, and management strategies for venous thromboembolism in pregnancy?
What are the risk factors, diagnosis, and management strategies for venous thromboembolism in pregnancy?
Low molecular weight heparin is the preferred pharmacological agent for the treatment and prevention of venous thromboembolism in pregnancy due to its safety profile.
Answers are grounded in this paper and cite their sources.
Supports LMWH preference in pregnancy VTE; leaves open need for prospective trials on dosing and alternatives.
Pregnancy-related venous thromboembolism (VTE) is one of the leading causes of maternal morbidity and mortality, in the antenatal and postpartum periods of pregnancy. The incidence of VTE during normal pregnancy four- to six-fold higher than in the general reproductive aged female population. Physiologic changes such as state, decreased venous capacitance, and reduced venous blood flow due to mechanical obstruction gravid uterus compromise this condition. The prominent risk factors for VTE are thrombophilia, history of disease and previous VTE, preeclampsia and related disorders, and Cesarean section. In case of suspicion VTE, prompt diagnosis and management are needed with the caution of potential adverse effects on the fetus. molecular weight heparin treatment is preferred due to better safety, more consistent bioavailability, ease of, lower risk of drug-related osteoporosis and thrombocytopenia and easier monitoring. For pregnant with acute VTE, adjusted-dose subcutaneous low molecular weight heparin should be administrated and continued for at least 6 weeks postpartum. For prevention of VTE, mechanical prophylaxis such physiotherapy, exercise, compression stockings, and intermittent pneumatic compression devices could be used. should also be considered for pregnant subjects with certain risks such as carriers of molecular or previously experienced VTE.
No takes yet. Share an insight, caveat, or question.
Joon Cheol Park (2016) conducted a review in Pregnancy-related venous thromboembolism. Low molecular weight heparin (LMWH) was evaluated. Low molecular weight heparin is the preferred safe treatment and prophylactic agent for pregnant women with acute venous thromboembolism or high-risk thrombophilia.
Synapse has enriched 10 related papers. Consider them for comparative context: